年龄相关性黄斑变性或厚脉络膜病相关静止性脉络膜新生血管的长期随访
回顾性分析67眼(65例)静止性1型脉络膜新生血管(CNV)患者,平均随访49.56±27.3个月。28眼出现激活,其中厚脉络膜病相关CNV较AMD相关CNV视力下降更少、脉络膜变薄更明显且抗VEGF注射次数更少。未激活眼的OCT-A生物标志物中仅CNV面积在24个月内显著增加。
要点
- 厚脉络膜病相关静止性CNV激活后抗VEGF注射次数0.09次,少于AMD相关CNV的0.21次(p=0.01)。
- 厚脉络膜病组激活后视力下降-3.28 ETDRS字母(p=0.7),AMD组下降-13.03 ETDRS字母(p=0.02)。
- 未激活的静止性CNV在24个月内仅CNV面积显著增加(厚脉络膜组+29.5%,p=0.01;AMD组+27.1%,p=0.03)。
核心结论
- 长期随访中,未激活的静止性CNV表现为CNV面积增加,其他OCT-A生物标志物无显著变化。
- 静止性1型CNV发生激活时,合并厚脉络膜病者对玻璃体腔注射(IVI)治疗的反应优于合并AMD者。
研究设计与样本
- 回顾性纳入2009年6月至2018年12月于巴黎东大学克雷泰伊眼科系和巴黎奥德翁眼科中心就诊的静止性1型CNV病例。
- 共纳入67眼(65例患者,女性43例,平均年龄76.63±9.7岁),平均随访49.56±27.3(12-112)个月,随访至少12个月。
- 对24个月内未出现CNV激活的眼行OCT-A定量分析CNV状态生物标志物(分形维数、腔隙度、血管密度、纵横比、CNV面积)。
主要发现
- 28眼出现静止性CNV激活,其中12眼为厚脉络膜病相关CNV,16眼为AMD相关CNV。
- 厚脉络膜病组激活后视力下降-3.28 ETDRS字母(p=0.7),AMD组下降-13.03 ETDRS字母(p=0.02)。
- 厚脉络膜病组脉络膜变薄-59.5 µm(p=0.03),AMD组变薄-16.36 µm(p=0.3)。
- 厚脉络膜病组抗VEGF玻璃体腔注射次数0.09次,少于AMD组的0.21次(p=0.01)。
- 24个月内未激活的静止性CNV中,仅CNV面积显著变化:厚脉络膜病组+29.5%(p=0.01),AMD组+27.1%(p=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate the long-term progression of quiescent type 1 choroidal neovascularisation (CNV) associated with age-related macular degeneration (AMD) or with pachychoroid disease. METHODS: All cases of quiescent type 1 CNV with a minimum follow-up of 12 months seen at the Department of Ophthalmology of University Paris Est, Creteil and at the Centre Ophtalmologique de l'Odeon, Paris, between June 2009 and December 2018 were retrospectively reviewed. Optical coherence tomography angiography (OCT-A) of eyes not showing CNV activation during 24 months was evaluated for quantitative analyses of CNV status biomarkers (fractal dimension, lacunarity, vessel density, aspect ratio, CNV area). RESULTS: A total of 67 eyes (65 patients, 43 females, mean age 76.63±9.7 years) with quiescent CNV and a mean follow-up of 49.56±27.3 (12-112) months were included. Of 28 eyes showing activation of quiescent CNV, 12 eyes with pachychoroid-associated CNV showed reduced visual loss (-3.28 ETDRS letters, p=0.7 vs -13.03 ETDRS letters, p=0.02), greater choroidal thinning (-59.5 µm, p=0.03 vs - 16.36 µm, p=0.3) and needed less antivascular endothelial growth factor intravitreal injections (IVI) (0.09 vs 0.21, p=0.01) than 16 eyes with AMD-associated CNV. CNV area was the only OCT-A biomarker to significantly change during 24 months in inactive quiescent CNV (+29.5%, p=0.01, in pachychoroid group and +27.1%, p=0.03, in the AMD group). CONCLUSION: In the long-term follow-up, inactive quiescent CNV showed an increase of CNV area without significant changes of the other OCT-A biomarkers. Quiescent type 1 CNV undergoing activation showed greater response to IVI when associated to pachychoroid.
引用
- Forte R, Coscas F, Serra R, et al. Long-term follow-up of quiescent choroidal neovascularisation associated with age-related macular degeneration or pachychoroid disease. Br J Ophthalmol. 2019. PMID: 31662311. doi:10.1136/bjophthalmol-2019-315189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。